AP NEWS

Gaucher’s Disease 2018-2028 - Forecast In 30 Major Markets - ResearchAndMarkets.com

July 12, 2018

DUBLIN--(BUSINESS WIRE)--Jul 12, 2018--The “Epiomic Epidemiology Series: Gaucher’s Disease Forecast In 30 Major Markets 2018-2028” report has been added to ResearchAndMarkets.com’s offering.

This report provides the current prevalent population for GD across 30 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Finland, Denmark, Austria, Greece, Romania, Slovenia, Czech Republic, Lithuania, Estonia, Russia, Turkey, Japan, China, South Korea, India, Brazil, Mexico, Argentina) split by gender and 5-year age cohort.

Along with the current prevalence, the report provides an overview of the genotypes and the prevalence of associated disorders of GD. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from our analysis team, several of the main co-morbidities of GD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for GD include:

Splenomegaly Hepatomegaly Haematological conditions Musculoskeletal conditions Gall stones

Reasons to buy

Able to quantify patient populations in global GD market to target the development of future products, pricing strategies and launch plans. Gain further insight into the prevalence of the subdivided types of GD and identify patient segments with high potential. Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries. Provide a level of understanding on the impact from specific co-morbid conditions on GD prevalent population. Examination of the prevalence of the different causative gene mutations for GD. Identify sub-populations within GD which require treatment. Gain an understanding of the specific markets that have the largest number of GD patients.

Key Topics Covered:

Introduction Cause of the Disease Risk Factors & Prevention Diagnosis of the Disease Variation by Geography/Ethnicity Disease Prognosis & Clinical Course Key Comorbid Conditions/Features Associated with the Disease Methodology for Quantification of Patient Numbers Top-Line Prevalence for Gaucher’s Disease Features of Gaucher’s Disease Patients Comorbidities of Gaucher’s Disease Patients Abbreviations used in the Report Other Services & Solutions Reports & Publications Online Epidemiology Databases Online Pharmaceutical Pricing Database References Appendix

For more information about this report visit https://www.researchandmarkets.com/research/cjx8s8/gauchers_disease?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180712005558/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/12/2018 10:43 AM/DISC: 07/12/2018 10:43 AM

http://www.businesswire.com/news/home/20180712005558/en

AP RADIO
Update hourly